CDE Indicates BTD Status for Visirna’s VSA001, Sperogenix’s Vamorolone, and Zai Lab’s Efgartigimod
The Center for Drug Evaluation (CDE) website has indicated that Visirna Therapeutics’ novel siRNA therapy...
HKG: 9688
Zai Lab’s Margenza (Margetuximab) Approved by China’s NMPA for HER2-Positive Breast Cancer
The National Medical Products Administration (NMPA) website has indicated that Zai Lab Ltd’s (NASDAQ: ZLAB,...
Novocure’s TTFields Misses Overall Survival Endpoint in Ovarian Cancer Phase III Trial
Switzerland-based Novocure (NASDAQ: NVCR) has experienced a setback with its Tumor Treating Fields (TTFields) product,...
Zai Lab Ltd Reports Q2 2023 Financials with 53% YOY Product Revenue Growth
China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its financial results for the...
Zai Lab and argenx Report Positive Preliminary Results from Vyvgart Hytrulo CIDP Study
China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) and its Netherlands-based partner argenx SE (NASDAQ:...
Zai Lab Initiates Phase III Trial for Bemarituzumab in First-Line Gastric Cancer Treatment
China-based biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced the first patient...
Zai Lab’s Vyvgart Receives NMPA Review for Subcutaneous Injection Form in gMG Treatment
China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has announced that the National Medical Products...
Zai Lab’s Vyvgart Receives NMPA Approval as First-in-Class FcRn Antagonist for Myasthenia Gravis
Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688), a China-based biopharmaceutical company, has announced that the...
Zai Lab and Novocure’s TTFields Show Survival Benefit in NSCLC, Despite Stock Plunge
China-based Zai Lab Ltd (ZLAB) (NASDAQ: ZLAB; HKG: 9688) and its partner Novocure Ltd (NASDAQ:...
Zai Lab Limited Reports Q1 2023 Financial Results and Product Highlights
China-based Zai Lab Limited (NASDAQ: ZLAB; HKG: 9688) has announced its financial results for the...
Zai Lab Partners with MediLink Therapeutics to Develop YL212 DLL3 ADC
Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688), a China-based biopharmaceutical company, has announced a strategic...
Zai Lab Reports 2022 Financial Results with Revenue Growth
China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) has announced its full-year 2022 financial results,...
Zai Lab to Present Zejula OS Study Results at ESMO Congress
China-based Zai Lab Limited (NASDAQ: ZLAB, HKG: 9688) is set to present two oral presentations...
Zai Lab’s SUL-DUR NDA Accepted for Review by NMPA
China-based Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has revealed that a New Drug Application...
Zai Lab Partners with Sir Run Run Shaw Hospital for Medical Innovation Center
Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced a strategic partnership agreement...
Zai Lab and Novocure’s TTFields Device Shows Survival Benefit in Lung Cancer Study
Shares in Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) and its partner Novocure...
Zai Lab Appoints Dr. Rafael Amado as President of Cancer R&D
Chinese biopharmaceutical company Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has announced the appointment of...
Zai Lab Reports 33% YOY Revenue Growth in Q3 2022
Chinese biopharmaceutical firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q3 2022 earnings...
Zai Lab Reports Strong Revenue Growth in 2022 Interim Results
Chinese biopharmaceutical firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has released its 2022 interim...
Zai Lab Licenses Seagen’s Tivdak for Greater China Development and Commercialization
Chinese firm Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) has formed a collaboration with US-based...